Table 4 Treatment-related adverse events in all patients (n = 40)
Adverse events | Grade1 | Grade2 | Grade3 | Grade4 |
|---|---|---|---|---|
Anorexia | 22(55.0%) | 5(12.5%) | 0 | 0 |
Leucopenia | 6(15.0%) | 16(40.0%) | 9(22.5%) | 1(2.5%) |
Anemia | 12(30.0%) | 15(37.5%) | 4(10.0%) | 0 |
Nausea | 15(37.5%) | 16(40.0%) | 0 | 0 |
Neutropenia | 9(22.5%) | 13(32.5%) | 4(10.0%) | 3(7.5%) |
Vomit | 15(37.5%) | 4(10.0%) | 0 | 0 |
Fatigue | 10(25.0%) | 18(45.0%) | 0 | 0 |
Thrombocytopenia | 9(22.5%) | 3(7.5%) | 1(2.5%) | 1(2.5%) |
Hypoalbuminemia | 13(32.5%) | 4(10.0%) | 0 | 0 |
Hypothyroidism | 18(45.0%) | 0 | 0 | 0 |
ALT increase | 4(10.0%) | 1(2.5%) | 0 | 0 |
Constipation | 16(40.0%) | 4(10.0%) | 0 | 0 |
Hyponatremia | 16(40.0%) | 12(30.0%) | 0 | 1(2.5%) |
AST increase | 3(7.5%) | 3(7.5%) | 0 | 0 |
Fever | 9(22.5%) | 3(7.5%) | 0 | 0 |
TSH increase | 13(32.5%) | 0 | 0 | 0 |
Pneumonia | 9(22.5%) | 1(2.5%) | 1(2.5%) | 0 |
Hyperglycemia | 18(45.0%) | 1(2.5%) | 0 | 0 |
UCB increase | 3(7.5%) | 0 | 0 | 0 |
CB increase | 3(7.5%) | 0 | 0 | 0 |
Mucositis | 4(10.0%) | 7(17.5%) | 0 | 0 |
Hypercreatinine | 1(2.5%) | 0 | 0 | 0 |
Hypokalaemia | 5(12.5%) | 1(2.5%) | 0 | 0 |
Venous thrombosis | 5(12.5%) | 3(7.5%) | 0 | 0 |
Rash | 1(2.5%) | 2(5%) | 0 | 0 |